BioAtla, Inc. (BCAB): restructuring charge — BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts

BioAtla, Inc.

Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
Workforce reduction of over 30%; estimated $0.5-$0.6M in severance costs mostly in Q2 2025.
BA3182 (CAB-EpCAM x CAB-CD3) Phase 1 dose escalation ongoing; data readout mid-2025; expansion data 1H 2026.
Mecbotamab vedotin (CAB-AXL-ADC): 66% 1-year OS, 58% 2-year OS in mKRAS NSCLC; median OS not reached.
Ozuriftamab vedotin (CAB-ROR2-ADC): 45% ORR (confirmed/unconfirmed) in HPV+ SCCHN; partnering discussions Q1 2025.

item 2.02 item 2.05 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

BioAtla, Inc. announced a restructuring with charges of $0.5 and $0.6 million (approximately 30%).

Type: restructuring
Charge: $0.5 and $0.6 million
Headcount: approximately 30%

Exact text from the filing

On March 27, 2025, the Company announced a workforce reduction of approximately 30%. The foregoing actions were committed to on March 21, 2025 and are intended to streamline the Company’s operating cost structure to support development of its prioritized programs and set the Company up for long-term success. The total cash payments related to this workforce reduction are estimated to be between $0.5 and $0.6 million related to employee severance and benefit costs.

View on SEC.gov

Browse all restructurings & charges →

BioAtla, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-046065

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.